Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2025 Rev YoY: N/A EPS YoY: -2,267.0% Move: +6.51%

Virax Biolabs Group

VRAX

$0.245 6.51%

Exchange NASDAQ Sector Healthcare Industry Biotechnology

Q2 2025

Published: Nov 20, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for VRAX

Reported

Report Date

Nov 20, 2024

Quarter Q2 2025

Revenue

4.95K

YoY: N/A

EPS

-0.89

YoY: -2,267.0%

Market Move

+6.51%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $0.00M up 0% year-over-year
EPS of $-0.89 decreased by 2% from previous year
Gross margin of -130.7%
Net income of -2.76M
""Our commitment to address the viral disease landscape provides us with a clear pathway to future revenues. We must effectively navigate these immediate challenges to unlock that potential," said the CEO." - CEO of Virax Biolabs

VRAX

Virax Biolabs Group Limited

Period Q2 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Virax Biolabs Group Limited (VRAX) reported a challenging Q2 2025, with a significant decline in revenue and heightened operational expenses. The company generated revenue of $4,953, reflecting a sharp 93.80% quarter-over-quarter (QoQ) decrease from the previous quarter. The financial metrics paint a troubling picture, with net income standing at a loss of $2,756,427, equating to an EPS of -$0.89, marking a staggering 2,267.02% decrease year-over-year (YoY).

The significant rise in R&D and operating expenses highlights the company's ongoing investment in innovation despite adverse market conditions. Management remains optimistic about future revenue streams stemming from new product introductions and strategic partnerships. However, investors should remain vigilant regarding the company's rising burn rate and the competitive landscape that continues to challenge its growth prospects.

Key Performance Indicators

Revenue

Stable

4.95K

QoQ: -93.80% | YoY: N/A

Gross Profit

Stable

-6.47K

-1.31% margin

QoQ: -116.16% | YoY: N/A

Operating Income

Decreasing

-2.88M

QoQ: 24.04% | YoY: -564.23%

Net Income

Decreasing

-2.76M

QoQ: 27.92% | YoY: -544.94%

EPS

Decreasing

-0.89

QoQ: 47.95% | YoY: -2 267.02%

Revenue Trend

Margin Analysis

Financial Highlights

### Financial Metrics Overview
- Revenue: $4,953 (QoQ: -93.80%)
- Net Income: -$2,756,427 (YoY: -544.94%, QoQ: +27.92%)
- Operating Income: -$2,878,891 (YoY: -564.23%, QoQ: +24.04%)
- Gross Profit: -$6,474 (QoQ: -116.16%)
- Cash at End of Period: $7,285,991

These metrics indicate deteriorating performance on multiple fronts but suggest a slight positive trend in net income QoQ, which might reflect tighter management of certain costs as the company looks ahead to operational efficiencies. The sharp decline in revenue reflects external challenges in the biotechnology sector, compounded by high operational costs.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	4.95K	N/A	-93.80%
Gross Profit	-6.47K	N/A	-116.16%
Operating Income	-2.88M	-564.23%	24.04%
Net Income	-2.76M	-544.94%	27.92%
EPS	-0.89	-2 267.02%	47.95%

Key Financial Ratios

Gross Profit Margin

Weak

-1.31%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

-581.24%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-556.52%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.29%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.32%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

11.58

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Conservative

0.07

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-0.55x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.70x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	0.00	-0.89	+0.0%	View
Q4 2024	0.08	-1.71	+1.0%	View
Q2 2024	0.08	-1.64	+1.0%	View
Q4 2023	0.00	-2.58	+103.0%	View
Q3 2023	0.00	-0.04	+0.0%	View

VRAX

Virax Biolabs Group

Q4 2024 Report

Virax Biolabs Group Limited (VRAX) Q4 2024 Results: Evaluating Operational Resilience Amidst Financial Strain...

Read full report

VRAX

Virax Biolabs Group

Q2 2024 Report

Virax Biolabs Group Limited (VRAX) Q2 2024 Financial Results - Assessing Recovery Opportunities in Biotechnology...

Read full report

VRAX

Virax Biolabs Group

Q4 2023 Report

Virax Biolabs Group Limited (VRAX) Q4 2023 Financial Analysis: Facing Challenges in a Rigorous Market...

Read full report

VRAX

Virax Biolabs Group

Q3 2023 Report

Virax Biolabs Group Limited (VRAX) Q3 2023 Financial Results: Analyzing Continued Losses Amidst Growth Challenges...

Read full report

Virax Biolabs Group (VRAX) Q2 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More VRAX Quarterly Reports

VRAX

VRAX

VRAX

VRAX

Q2 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

VRAX Full Profile

VRAX Financial Statements

Earnings Calendar